Linked Life Data

15607796

Source:http://linkedlifedata.com/resource/pubmed/id/15607796

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2004-12-20
pubmed:abstractText
Previous studies from numerous laboratories have demonstrated that inhibitory class I binding NK receptors dominate functional interactions in vitro. Our previous studies have shown that in addition to lysis, a major consequence of triggering the murine activating NK receptor Ly49D is the expression of cytokines and chemokines. We have recently shown that the activating Ly49D murine NK cell receptor can potently synergize during co-stimulation with IL-12 and IL-18 for selective production of IFN-gamma. Activation both in vitro and in vivo and synergistic production of IFN-gamma by Ly49D expressing NK cells results from cytokine stimulation combined with co-receptor ligation. In addition, IL-12 is capable of overriding the inhibitory receptor blockade for cytokine production, both in vitro and in vivo. Our current studies will expand this finding of IL-12 synergy to other receptors in the NK repertoire and evaluate potential biochemical mechanisms involved in this synergy. These findings place NK cells and their activating Ly49 receptors as important initiators of microbial, antiviral and anti-tumor immunity and provide a mechanism for the release of activating Ly49 receptors from an inhibitory receptor blockade. Discussion of how activation of the innate immune system provides important initiators of adaptive immune responses by receptor cross-linking and cytokine co-receptor engagement will ensue.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0161-5890
pubmed:author
pubmed:issnType
Print
pubmed:volume
42
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
445-50
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Mouse Ly49 NK receptors: balancing activation and inhibition.
pubmed:affiliation
Laboratory of Experimental Immunology, National Cancer Institute-Center for Cancer Research, 560/31-93, Frederick, MD 21702-1201, USA. ortaldo@ncifcrf.gov
pubmed:publicationType
Journal Article, Review